home / stock / biib / biib quote
Last: | $225.27 |
---|---|
Change Percent: | -0.5% |
Open: | $227.73 |
Close: | $226.40 |
High: | $228.48 |
Low: | $223.62 |
Volume: | 270,073 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$225.27 | $227.73 | $226.4 | $228.48 | $223.62 | 270,073 | 07-22-2024 |
$226.4 | $225.67 | $226.4 | $227.625 | $222.38 | 843,240 | 07-19-2024 |
$225.25 | $226 | $225.25 | $231.27 | $223.3 | 856,347 | 07-18-2024 |
$228.33 | $223.39 | $228.33 | $230.0999 | $221.67 | 949,485 | 07-17-2024 |
$225.02 | $221.79 | $225.02 | $228.57 | $220.81 | 1,006,178 | 07-16-2024 |
$221.58 | $230.06 | $221.58 | $230.06 | $221.21 | 1,381,797 | 07-15-2024 |
$230.06 | $237.98 | $230.06 | $238 | $226.5 | 1,473,172 | 07-12-2024 |
$236.8 | $234.5 | $236.8 | $237.98 | $232.47 | 667,222 | 07-11-2024 |
$232.75 | $229.85 | $232.75 | $232.82 | $227.92 | 522,604 | 07-10-2024 |
$229.06 | $227.71 | $229.06 | $229.33 | $225.59 | 518,862 | 07-09-2024 |
$228.07 | $226.47 | $228.07 | $229.415 | $225.8 | 535,613 | 07-08-2024 |
$225.65 | $225.03 | $225.65 | $226.42 | $223.05 | 458,329 | 07-05-2024 |
$224.61 | $229.45 | $224.61 | $229.45 | $222.735 | 580,741 | 07-04-2024 |
$224.61 | $229.45 | $224.61 | $229.45 | $222.735 | 580,741 | 07-03-2024 |
$228.82 | $231.71 | $228.82 | $233.17 | $225.1 | 860,229 | 07-02-2024 |
$231.77 | $231.41 | $231.77 | $236.81 | $230.645 | 862,657 | 07-01-2024 |
$231.82 | $229.5 | $231.82 | $235.49 | $227.73 | 2,242,754 | 06-28-2024 |
$228.72 | $223.43 | $228.72 | $230.12 | $222.79 | 1,005,470 | 06-27-2024 |
$224.46 | $221.79 | $224.46 | $225.11 | $220.02 | 861,260 | 06-26-2024 |
$223.19 | $225.48 | $223.19 | $229.53 | $222.83 | 812,590 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...